Corcept Therapeutics (CORT) Tax Provisions (2017 - 2026)

Corcept Therapeutics has reported Tax Provisions for 10 years, with the latest figure at $2.9 million in Q2 2026.

• Quarterly Tax Provisions rose 184.11% year-over-year to $2.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$28.9 million (down 284.02% YoY) and the FY2025 annual result came in at -$33.2 million, down 263.62% from the prior year.
• Tax Provisions improved to $2.9 million in Q2 2026 per CORT's latest filing, from -$13.0 million in the prior quarter.
• Over five years, Tax Provisions peaked at $7.7 million in Q4 2022 and troughed at -$14.4 million in Q4 2025.
• A 5-year average of $570000.0 and a median of $3.5 million in 2022 frame the typical range for Tax Provisions.
• The sharpest annual moves came in 2023 and 2025: Tax Provisions soared 412.16% in 2023, then slumped 1314.36% in 2025.
• Over 5 years, Tax Provisions stood at $7.7 million in 2022, then slipped by 29.4% to $5.4 million in 2023, then slumped by 78.14% to $1.2 million in 2024, then plunged by 1314.36% to -$14.4 million in 2025, then jumped by 120.48% to $2.9 million in 2026.
• According to Business Quant data, Tax Provisions over the past three periods registered $2.9 million, -$13.0 million, and -$14.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.